Pharmacology Quiz: Asthma Copd Stepwise Therapy
20 questions · exam conditions
0:00
Asthma Copd Stepwise TherapyQuestion 1 of 20

A 62-year-old lifelong non-smoker with a history of adult-onset allergies presents with wheezing and dyspnea. Spirometry shows an FEV1/FVC ratio of 0.68, which improves by 18% and 250 mL after albuterol administration. Blood eosinophils are 400 cells/μL. This presentation is suggestive of Asthma-COPD Overlap (ACO). Which initial controller therapy would be most appropriate?

Tiotropium (LAMA) monotherapy.
Salmeterol (LABA) monotherapy.
Low-dose fluticasone/salmeterol (ICS/LABA).
Roflumilast.
← Back to quizzes

Pharmacology Quiz

Pharmacology Quiz: Asthma Copd Stepwise Therapy

Practice Asthma Copd Stepwise Therapy in Pharmacology with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Asthma Copd Stepwise Therapy, giving you a quick way to practice the rules, question types, and explanations that matter most for Pharmacology.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

A 62-year-old lifelong non-smoker with a history of adult-onset allergies presents with wheezing and dyspnea. Spirometry shows an FEV1/FVC ratio of 0.68, which improves by 18% and 250 mL after albuterol administration. Blood eosinophils are 400 cells/μL. This presentation is suggestive of Asthma-COPD Overlap (ACO). Which initial controller therapy would be most appropriate?

  1. Tiotropium (LAMA) monotherapy.
  2. Salmeterol (LABA) monotherapy.
  3. Low-dose fluticasone/salmeterol (ICS/LABA). (correct answer)
  4. Roflumilast.
Explanation: This patient has features of both asthma (non-smoker, allergies, significant bronchodilator reversibility, high eosinophils) and COPD (persistent airflow limitation). In cases of diagnostic uncertainty or ACO, treatment should always include an inhaled corticosteroid (ICS) due to the risks associated with untreated asthma. Therefore, an ICS/LABA combination is the most appropriate initial therapy. LAMA or LABA monotherapy would fail to treat the underlying inflammation and would be dangerous if the predominant process is asthma. Roflumilast is for specific COPD phenotypes.

Question 2

A 20-year-old is diagnosed with mild persistent asthma, with symptoms occurring about 3 times per week. According to the GINA guidelines' preferred approach (Track 1) for initial therapy at Step 2, which regimen is recommended?

  1. Daily low-dose ICS plus an as-needed SABA for relief.
  2. As-needed SABA monotherapy.
  3. As-needed low-dose ICS/formoterol combination. (correct answer)
  4. Daily leukotriene receptor antagonist (LTRA).
Explanation: The GINA guidelines have evolved. For mild asthma (Steps 1 and 2), the preferred approach (Track 1) is to use an as-needed low-dose ICS/formoterol combination for both reliever and controller therapy. This ensures that the patient receives an anti-inflammatory ICS whenever they experience symptoms. Daily low-dose ICS plus as-needed SABA is the alternative approach (Track 2). As-needed SABA alone is no longer recommended for persistent asthma due to risks associated with SABA overuse without an ICS. LTRAs are less effective alternatives.

Question 3

A 72-year-old patient with COPD has been on triple therapy (ICS/LABA/LAMA) for three years. He has been exacerbation-free for the past year but has developed pneumonia twice in that period. His most recent blood eosinophil count is 80 cells/μL. What is the most appropriate therapeutic adjustment?

  1. Continue current triple therapy and add prophylactic antibiotics.
  2. Discontinue the LAMA component.
  3. Discontinue the inhaled corticosteroid (ICS) component. (correct answer)
  4. Switch to a different ICS/LABA combination.
Explanation: GOLD guidelines recommend considering ICS withdrawal in patients with a history of pneumonia, a low likelihood of ICS benefit (eosinophils < 100 cells/μL), and who are stable without exacerbations. This patient meets all criteria. Discontinuing the ICS and continuing with dual LAMA/LABA bronchodilation is the most appropriate step to reduce the risk of future pneumonia without compromising control. Bronchodilators (LAMA, LABA) are the foundation of COPD therapy and should not be discontinued.

Question 4

A patient with stable COPD on LAMA/LABA therapy reports a persistently high CAT score of 22, primarily due to dyspnea. They have not had an exacerbation in over a year. Pharmacologic therapy has been optimized. Which intervention should be prioritized as the next step in their management plan?

  1. Addition of an inhaled corticosteroid.
  2. A trial of roflumilast.
  3. Enrollment in a comprehensive pulmonary rehabilitation program. (correct answer)
  4. Switching to a different LAMA/LABA combination product.
Explanation: When a COPD patient on optimal dual bronchodilator therapy still has persistent dyspnea (the 'dyspnea pathway' in GOLD), non-pharmacologic interventions are crucial. Pulmonary rehabilitation is a cornerstone of COPD management that has been proven to improve dyspnea, exercise capacity, and quality of life. Adding an ICS or roflumilast is indicated for patients with an exacerbation-predominant phenotype. Switching inhaler devices without a clear reason is unlikely to provide significant benefit.

Question 5

A patient with moderate persistent asthma is well-controlled on a daily maintenance inhaler of fluticasone propionate/salmeterol. What is the appropriate medication to be prescribed for as-needed quick relief of symptoms?

  1. A second dose of their fluticasone/salmeterol inhaler.
  2. An as-needed low-dose budesonide/formoterol inhaler.
  3. An as-needed short-acting beta-agonist (SABA) inhaler. (correct answer)
  4. An as-needed ipratropium bromide inhaler.
Explanation: When a patient's maintenance therapy is a non-formoterol-containing ICS/LABA combination (like fluticasone/salmeterol), the designated reliever medication is a SABA (e.g., albuterol). Salmeterol has a slow onset of action and is not suitable for quick relief. Using an ICS/formoterol inhaler as a reliever is only appropriate when it is also the maintenance inhaler (MART/SMART therapy). Ipratropium, a SAMA, is not the first-line reliever for asthma.

Question 6

A 67-year-old male with severe COPD (FEV1 35% predicted) and chronic bronchitis is on triple therapy (ICS/LAMA/LABA). He continues to have frequent exacerbations despite optimal inhaler technique. His blood eosinophil count is 90 cells/μL. What is the most appropriate next therapeutic addition?

  1. Omalizumab
  2. Increase the dose of the inhaled corticosteroid.
  3. Long-term oral prednisone
  4. Roflumilast (correct answer)
Explanation: When treating severe COPD patients with frequent exacerbations despite optimal triple therapy, you need to consider add-on therapies based on specific patient characteristics and phenotypes. This patient has severe COPD with chronic bronchitis phenotype and continues exacerbating despite ICS/LAMA/LABA therapy. The key detail is his low eosinophil count (90 cells/μL), which helps guide treatment selection. Roflumilast (D) is the correct choice because it's a phosphodiesterase-4 (PDE4) inhibitor specifically indicated for severe COPD patients with chronic bronchitis phenotype and frequent exacerbations. It reduces inflammation by increasing cyclic adenosine monophosphate (cAMP) levels and is particularly effective in patients with lower eosinophil counts. Omalizumab (A) is an anti-IgE monoclonal antibody used primarily for allergic asthma, not COPD. It's inappropriate here since this patient has COPD without evidence of allergic disease. Increasing ICS dose (B) is unlikely to provide additional benefit and may increase side effects, especially since he already has low eosinophils (suggesting less steroid-responsive inflammation). Long-term oral prednisone (C) is generally avoided in COPD due to significant systemic side effects including osteoporosis, diabetes, and increased infection risk, with minimal proven benefit for stable disease. Remember that COPD add-on therapy selection depends on phenotype identification: roflumilast works best for chronic bronchitis with frequent exacerbations, while newer biologics target specific inflammatory pathways. Always consider eosinophil count as it helps predict steroid responsiveness and guides personalized treatment decisions.

Question 7

A patient with moderate persistent asthma is well-controlled on a daily maintenance inhaler of fluticasone propionate/salmeterol. What is the appropriate medication to be prescribed for as-needed quick relief of symptoms?

  1. A second dose of their fluticasone/salmeterol inhaler.
  2. An as-needed low-dose budesonide/formoterol inhaler.
  3. An as-needed short-acting beta-agonist (SABA) inhaler. (correct answer)
  4. An as-needed ipratropium bromide inhaler.
Explanation: When a patient's maintenance therapy is a non-formoterol-containing ICS/LABA combination (like fluticasone/salmeterol), the designated reliever medication is a SABA (e.g., albuterol). Salmeterol has a slow onset of action and is not suitable for quick relief. Using an ICS/formoterol inhaler as a reliever is only appropriate when it is also the maintenance inhaler (MART/SMART therapy). Ipratropium, a SAMA, is not the first-line reliever for asthma.

Question 8

A 22-year-old with moderate persistent asthma admits to being frequently non-adherent with their daily controller inhaler. To simplify the regimen and improve adherence, their physician suggests a strategy using a single inhaler for both maintenance and reliever therapy (MART/SMART). Which medication combination is suitable for this strategy?

  1. Fluticasone/salmeterol
  2. Budesonide/formoterol (correct answer)
  3. Ipratropium/albuterol
  4. Tiotropium/olodaterol
Explanation: The MART (Maintenance and Reliever Therapy) or SMART (Single Maintenance and Reliever Therapy) strategy requires an ICS combined with a LABA that has a fast onset of action. Formoterol has a rapid onset (within 1-3 minutes), similar to albuterol, making budesonide/formoterol suitable for this purpose. Salmeterol (in fluticasone/salmeterol) has a slower onset and is not approved for use as a reliever. Ipratropium/albuterol is a SAMA/SABA combination used for COPD, and tiotropium/olodaterol is a LAMA/LABA for COPD maintenance.

Question 9

A 22-year-old with moderate persistent asthma admits to being frequently non-adherent with their daily controller inhaler. To simplify the regimen and improve adherence, their physician suggests a strategy using a single inhaler for both maintenance and reliever therapy (MART/SMART). Which medication combination is suitable for this strategy?

  1. Fluticasone/salmeterol
  2. Budesonide/formoterol (correct answer)
  3. Ipratropium/albuterol
  4. Tiotropium/olodaterol
Explanation: The MART (Maintenance and Reliever Therapy) or SMART (Single Maintenance and Reliever Therapy) strategy requires an ICS combined with a LABA that has a fast onset of action. Formoterol has a rapid onset (within 1-3 minutes), similar to albuterol, making budesonide/formoterol suitable for this purpose. Salmeterol (in fluticasone/salmeterol) has a slower onset and is not approved for use as a reliever. Ipratropium/albuterol is a SAMA/SABA combination used for COPD, and tiotropium/olodaterol is a LAMA/LABA for COPD maintenance.

Question 10

A 40-year-old patient's asthma is inadequately controlled on a medium-dose ICS/LABA combination. They use their reliever inhaler most days of the week and have an FEV1 of 68% predicted. According to GINA guidelines, which intervention is a recommended next step (Step 4 to Step 5)?

  1. Refer for phenotypic assessment and consideration of add-on therapy like a LAMA. (correct answer)
  2. Add a daily leukotriene receptor antagonist (montelukast).
  3. Switch to a high-dose ICS monotherapy regimen.
  4. Initiate a short course of oral corticosteroids and then return to current therapy.
Explanation: The patient is at GINA Step 4 and is not controlled. The next step is to move to Step 5, which involves referral to a specialist for phenotypic assessment. Add-on therapies at this stage include a LAMA (e.g., tiotropium), or biologic agents if specific criteria are met. While increasing to high-dose ICS/LABA is also a Step 4/5 option, referral and considering a new class like a LAMA is a key part of this step-up. Montelukast is a less effective add-on at this stage. Oral corticosteroids are for acute exacerbations, not chronic step-up. Switching to high-dose ICS monotherapy would be a step-down in bronchodilation and is inappropriate.

Question 11

A 58-year-old with a 30-pack-year smoking history presents with cough and dyspnea. After a thorough workup including spirometry, a definitive diagnosis of asthma is made. Which of the following initial controller monotherapy regimens would be contraindicated?

  1. Low-dose budesonide
  2. Montelukast
  3. Low-dose fluticasone
  4. Salmeterol (correct answer)
Explanation: In patients with asthma, long-acting beta-agonist (LABA) monotherapy, such as with salmeterol, is contraindicated. It has been associated with an increased risk of asthma-related death when not used in combination with an inhaled corticosteroid (ICS). Although LABA monotherapy is an acceptable treatment for COPD, the patient's definitive diagnosis is asthma, making this choice incorrect and dangerous. Low-dose ICS (budesonide, fluticasone) is the cornerstone of asthma controller therapy, and montelukast is an alternative.

Question 12

A 75-year-old man is newly diagnosed with GOLD Group B COPD. His medical history is significant for severe benign prostatic hyperplasia (BPH) with urinary retention and glaucoma. Which initial monotherapy would be the most prudent choice?

  1. Tiotropium (LAMA)
  2. Indacaterol (LABA) (correct answer)
  3. Aclidinium (LAMA)
  4. Budesonide (ICS)
Explanation: Both tiotropium and aclidinium are LAMAs, which act as anticholinergics. Anticholinergic agents can worsen urinary retention in patients with BPH and can precipitate acute angle-closure glaucoma. Therefore, a LABA such as indacaterol would be a safer initial choice for bronchodilation in this patient. ICS monotherapy is not recommended for COPD.

Question 13

A 29-year-old woman who is 18 weeks pregnant has worsening asthma symptoms, requiring her SABA 3-4 times per week. She is not currently on any controller medication. Which of the following is the most appropriate controller medication to initiate, based on extensive safety data in pregnancy?

  1. Montelukast
  2. Oral theophylline
  3. Inhaled fluticasone/salmeterol
  4. Inhaled budesonide (correct answer)
Explanation: When treating asthma in pregnancy, you need to balance effective symptom control with fetal safety. This patient's symptoms (requiring SABA 3-4 times weekly) indicate inadequate control that warrants controller therapy, as uncontrolled asthma poses greater risks to both mother and fetus than appropriately chosen medications. Inhaled budesonide (D) is the most appropriate choice because it has the most extensive safety data in pregnancy among inhaled corticosteroids. Multiple large studies and registries have demonstrated no increased risk of birth defects or adverse pregnancy outcomes. The FDA classifies it as pregnancy category B, and major guidelines specifically recommend budesonide as the preferred inhaled corticosteroid during pregnancy. Montelukast (A) has limited pregnancy safety data compared to budesonide. While it's pregnancy category B, the evidence base is much smaller, making it a second-line option when inhaled corticosteroids are contraindicated or ineffective. Oral theophylline (B) has a narrow therapeutic window requiring frequent monitoring, and serum levels can be unpredictably altered by pregnancy-related physiological changes. It also carries risks of maternal and fetal toxicity. The fluticasone/salmeterol combination (C) contains fluticasone, which has less pregnancy safety data than budesonide. Additionally, starting with a combination therapy bypasses the stepwise approach recommended in pregnancy management. Remember this principle: for asthma in pregnancy, budesonide is the gold-standard inhaled corticosteroid due to its extensive safety profile. When you see pregnancy + asthma controller therapy, think budesonide first.

Question 14

A 45-year-old patient with persistent asthma is currently managed with a low-dose inhaled corticosteroid (ICS). They report using their albuterol inhaler 4-5 times per week for symptom relief and have been awakened by coughing twice in the past month. Their FEV1 is 75% of predicted. According to GINA guidelines, what is the most appropriate next step in management?

  1. Increase the dose of the inhaled corticosteroid to medium-dose.
  2. Add a long-acting beta-agonist (LABA) to the current low-dose ICS. (correct answer)
  3. Add a long-acting muscarinic antagonist (LAMA) to the current regimen.
  4. Initiate montelukast and continue the low-dose ICS.
Explanation: The patient's symptoms indicate that their asthma is not well-controlled on low-dose ICS monotherapy (Step 2). The preferred next step (Step 3) in the GINA guidelines for adults is to add a LABA to the low-dose ICS. While increasing the ICS to a medium dose is an alternative, adding a LABA is generally preferred and often more effective for improving lung function and reducing symptoms. Adding a LAMA is typically reserved for Step 4 or 5. Adding montelukast is an alternative but is generally less effective than adding a LABA.

Question 15

A 68-year-old male with a significant smoking history is newly diagnosed with COPD. His FEV1 is 48% of predicted. He reports an mMRC dyspnea scale score of 3 and has been hospitalized once for an acute exacerbation in the past year. His blood eosinophil count is 150 cells/μL. Based on the GOLD 2023 guidelines, what is the most appropriate initial pharmacologic therapy?

  1. A long-acting muscarinic antagonist (LAMA) monotherapy.
  2. An inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA) combination.
  3. A long-acting muscarinic antagonist (LAMA) and long-acting beta-agonist (LABA) combination. (correct answer)
  4. A short-acting beta-agonist (SABA) as needed for symptoms.
Explanation: The patient's high symptom burden (mMRC > 2) and history of a severe exacerbation (hospitalization) place him in GOLD Group D. The recommended initial therapy for Group D is a LAMA/LABA combination. LAMA monotherapy is for Group C. An ICS/LABA could be considered if eosinophils were >300 cells/μL, but at 150, dual bronchodilation is the preferred starting point. SABA as needed is only appropriate for low-risk, low-symptom Group A patients.

Question 16

A patient with severe eosinophilic asthma is maintained on high-dose ICS/LABA and tiotropium. To gain control, they require frequent courses of oral prednisone and are considered oral corticosteroid-dependent. Addition of which agent is most likely to have a significant oral corticosteroid-sparing effect in this patient?

  1. Benralizumab (correct answer)
  2. Theophylline
  3. Cromolyn sodium
  4. Roflumilast
Explanation: Benralizumab is a biologic agent that targets the IL-5 receptor alpha on eosinophils, leading to their depletion. In patients with severe, uncontrolled eosinophilic asthma, anti-IL-5 pathway biologics (like benralizumab, mepolizumab, reslizumab) have been shown to significantly reduce exacerbations and decrease the required daily dose of oral corticosteroids. Theophylline and cromolyn are older, less effective agents. Roflumilast is indicated for COPD, not asthma.

Question 17

A 65-year-old patient with GOLD Group B COPD is being treated with tiotropium (a LAMA). At a 3-month follow-up visit, they have had no exacerbations but continue to complain of significant dyspnea (mMRC score of 2). According to the GOLD follow-up algorithm, what is the most appropriate adjustment to their therapy?

  1. Add an inhaled corticosteroid (ICS).
  2. Add a long-acting beta-agonist (LABA). (correct answer)
  3. Add roflumilast.
  4. Switch from tiotropium to a LABA.
Explanation: The patient's predominant treatable trait is dyspnea, not exacerbations. The GOLD follow-up algorithm for persistent dyspnea on monotherapy recommends escalating to dual bronchodilator therapy. Therefore, adding a LABA to the existing LAMA is the correct step. Adding an ICS or roflumilast is recommended for the exacerbation pathway, not for managing persistent dyspnea alone. Switching from a LAMA to a LABA would be a lateral move and is less effective than using both together.

Question 18

A patient with severe eosinophilic asthma is maintained on high-dose ICS/LABA and tiotropium. To gain control, they require frequent courses of oral prednisone and are considered oral corticosteroid-dependent. Addition of which agent is most likely to have a significant oral corticosteroid-sparing effect in this patient?

  1. Benralizumab (correct answer)
  2. Theophylline
  3. Cromolyn sodium
  4. Roflumilast
Explanation: Benralizumab is a biologic agent that targets the IL-5 receptor alpha on eosinophils, leading to their depletion. In patients with severe, uncontrolled eosinophilic asthma, anti-IL-5 pathway biologics (like benralizumab, mepolizumab, reslizumab) have been shown to significantly reduce exacerbations and decrease the required daily dose of oral corticosteroids. Theophylline and cromolyn are older, less effective agents. Roflumilast is indicated for COPD, not asthma.

Question 19

A 34-year-old patient with asthma has been well-controlled on a medium-dose fluticasone/salmeterol inhaler (ICS/LABA) for the past 6 months, with no exacerbations and minimal SABA use. A decision is made to attempt a step-down in therapy. Which of the following is the most appropriate initial step-down strategy?

  1. Discontinue the salmeterol (LABA) component and continue medium-dose fluticasone.
  2. Discontinue all controller therapy and manage with an as-needed SABA only.
  3. Reduce the regimen to a low-dose fluticasone/salmeterol combination inhaler. (correct answer)
  4. Discontinue the fluticasone (ICS) component and continue salmeterol monotherapy.
Explanation: When a patient's asthma is well-controlled for at least 3 months, a step-down in therapy can be considered to find the lowest effective dose. The preferred initial step-down from a medium-dose ICS/LABA is to reduce it to a low-dose ICS/LABA. Stopping the LABA completely is another option but reducing the ICS dose first while maintaining dual therapy is often preferred. Stopping all controller therapy is inappropriate for a patient who required a medium-dose ICS/LABA for control. Discontinuing the ICS while continuing the LABA is contraindicated in asthma due to increased risk of severe exacerbations.

Question 20

A patient with severe COPD is maintained on dual bronchodilator therapy (LAMA/LABA). Despite this, they have experienced two moderate exacerbations in the past year. The physician is considering adding an inhaled corticosteroid (ICS). The addition of an ICS is most strongly supported by which of the following laboratory findings?

  1. Blood eosinophil count > 300 cells/μL (correct answer)
  2. Forced expiratory volume in 1 second (FEV1) < 50% predicted
  3. Elevated serum IgE levels
  4. A history of pneumonia in the last 2 years
Explanation: According to GOLD guidelines, the strongest predictor of a positive response to inhaled corticosteroids for exacerbation reduction in COPD is a peripheral blood eosinophil count > 300 cells/μL. While a low FEV1 was historically used, eosinophil count is now the preferred biomarker. Elevated IgE is relevant for allergic asthma, not typically for guiding ICS therapy in COPD. A history of pneumonia is a relative contraindication to ICS therapy, as it can increase pneumonia risk.